Pinealon Research: Neuroprotection, Prenatal and Geriatric Trial Data
Pinealon has a well-documented footprint in Russian and Eastern European literature, spanning human clinical tracking, animal models and in-vitro cellular assays. This page walks through what each study actually measured and how the compound was delivered.
Mechanism of action
Pinealon is a synthetic tripeptide built from three amino acids — glutamic acid, aspartic acid and arginine (Glu-Asp-Arg, or EDR). It was developed by Vladimir Khavinson and colleagues at the St Petersburg Institute of Bioregulation and Gerontology and belongs to the family known as Khavinson bioregulators.
Where its parent peptide Epitalon targets systemic ageing broadly via the pineal gland, Pinealon was synthesised specifically to move readily across blood-brain barrier pathways and act on brain cortex and central nervous system tissue.
The proposed mechanism is epigenetic rather than receptor-based: short peptides of this class are described as entering the cell nucleus and interacting with DNA to influence which genes are switched on — in Pinealon's case, genes associated with neuronal survival and antioxidant defence.
Because it is only three amino acids long, Pinealon is unusually stable and low in molecular weight compared with larger proteins, which is why the literature covers both subcutaneous injection and intranasal delivery.
The studies
The four strands below cover the main directions of the published work: direct cell-level protection in a dish, prenatal protection in rodent offspring, neurochemical stabilisation under hypoxia and hypothermia, and a small human geriatric trial.
In-vitro suppression of free radicals and cell death
To see whether Pinealon can directly shield neurons from physical decay, researchers looked at how isolated nervous-system cells behave when flooded with a toxic, cell-killing chemical.
In-vitro cell culture assay · isolated cerebellar granule cells, rat neutrophils and pheochromocytoma (PC12) cells treated with Pinealon before exposure to 1 mM hydrogen peroxide
- Significantly restricted
- Free-radical accumulation
- ~Halved
- Necrotic cell mortality
- Delayed
- ERK 1/2 activation
under oxidative strain
at higher concentrations
Benefits shown in the data
- The ultra-short tripeptide chain can cross cell membranes, neutralise reactive oxygen species and block necrotic cell-death pathways.
- Assays showed Pinealon significantly restricted free-radical accumulation and halved necrotic cell mortality under intense oxidative strain.
- At low concentrations it behaved as a classic antioxidant; at higher concentrations it delayed ERK 1/2 activation and altered the cell cycle, which the authors read as evidence of direct interaction with the cell genome to switch on survival programmes.
- The concentration-dependent switch is the interesting part: the same peptide looks like a simple antioxidant at low levels and a gene-level regulator at higher ones.
- This is isolated cells in a dish — it establishes a mechanism, and the animal and human strands below are what test whether it carries through to a whole organism.
Protecting offspring from prenatal brain damage
Hyperhomocysteinemia during pregnancy cuts oxygen and nutrient flow to a developing fetus, frequently leaving offspring with cognitive deficits and brain lesions. This work tested whether treating the mother protects the offspring's brain.
Systemic/subcutaneous maternal administration · pregnant rats with induced high homocysteine, with offspring brain tissue and behaviour tracked after birth
- Fully preserved
- Spatial orientation
- Preserved
- Learning ability
- Significantly lower
- Neuronal necrosis
in offspring
Benefits shown in the data
- Prenatal Pinealon completely preserved the offspring's spatial orientation and learning ability in behavioural testing.
- Neurons isolated from the cerebellums of treated offspring were markedly more resistant to oxidative stress.
- Those same cells showed a significantly lower rate of tissue necrosis than untreated controls.
- This is the strongest bridge in the Pinealon literature between the cell-dish antioxidant finding and a measurable whole-animal outcome: the behaviour and the tissue data point the same way.
- The model is a specific, severe prenatal insult (induced hyperhomocysteinemia), so it speaks to protection under that particular stress rather than to normal development.
Behavioural and neurochemical balance under hypoxia and hypothermia
Extreme environmental stress — severe oxygen deprivation or a dangerous drop in body temperature — drains the brain's baseline neurotransmitter pools. This series tested whether Pinealon holds those pools steady.
Systemic injection series · 18-month-old rats given Pinealon or Cortexin, then subjected to acute hypobaric hypoxia or mild hypothermia
- Accumulated
- Adrenergic mediators
- Increased
- Cortical serotonin
- Preserved
- Behaviour under stress
protective response
Benefits shown in the data
- Pinealon drove accumulation of protective adrenergic mediators and raised serotonin levels in the cerebral cortex during stress challenges.
- Treated animals maintained normal behaviour where untreated animals showed stress-related decline.
- The proposed route is regulation of neurotransmitter pools alongside suppression of caspase-3-driven programmed cell death.
- The comparison is informative: Cortexin had the stronger immediate effect on free-radical processes, while Pinealon functioned more as a steady metabolic stabiliser.
- The use of aged (18-month) animals matters — the effect was measured in a nervous system already under age-related strain, not in young healthy tissue.
Human geriatric trial in organic brain syndrome
To test whether the preclinical findings translate to people, researchers tracked ageing adults living with vascular or traumatic brain issues through a course of the peptide.
Human clinical tracking · 32 elderly patients aged 41-83 with polymorbidity and organic brain syndrome in remission, treated with Pinealon and Vesugen
- Markedly improved
- CNS general activity
- Highly significant
- Anabolic / neuroprotective effect
- Unchanged
- Chromatin condensation
non-mutagenic
Benefits shown in the data
- Intramuscular or subcutaneous courses were associated with a highly significant anabolic and neuroprotective effect.
- General central nervous system activity improved markedly across the cohort, alongside movement in biological-age and metabolic markers.
- Genetic tracking showed no alteration to chromatin condensation, which the authors read as evidence the peptide is non-mutagenic at the nuclear level.
- The chromatin result is the most useful safety data point in the Pinealon literature — it directly addresses the obvious question raised by an epigenetic mechanism.
- The cohort is small (32 patients) and Pinealon was given alongside Vesugen, so the two peptides' contributions cannot be separated from this study alone.
Storage & handling
Pinealon is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water added slowly down the inner wall of the vial; swirl gently until fully dissolved and never shake.
Store reconstituted solution at 2-8 °C and use within your lab's defined stability window. Avoid repeated freeze-thaw cycles.
Delivery context: subcutaneous vs nasal
Because Pinealon is an ultra-short tripeptide, it is far more stable than large proteins and survives both routes well. The literature uses each for different purposes.
| Route | Typical research use | What the research shows |
|---|---|---|
| Subcutaneous injection | 10-20 day cycles | Favoured for deep, system-wide neuroprotection and biological-age marker work. Most of the animal and human data above uses systemic administration on a course basis rather than a single dose. |
| Intranasal (nasal spray) | Acute / cognitive protocols | Low molecular weight makes nasal delivery highly effective — the peptide reaches the brain via the olfactory nerve pathways rather than having to cross the blood-brain barrier from circulation, giving a much faster onset. This is the route of interest for immediate cognitive and acute brain-injury research. |
Pinealon research context
A few points help in reading this literature accurately.
The evidence base is largely Russian and Eastern European
Most Pinealon work comes from Khavinson's group and allied institutes, published in Russian-language and Eastern European journals. That is where this class of peptide was developed and where the specialist expertise sits — but it does mean there is limited independent Western replication to cross-check against.
The human trial is small and used two peptides together
The geriatric study tracked 32 patients receiving Pinealon alongside Vesugen. The improvements recorded are real measurements, but a combined protocol in a small cohort cannot separate which peptide produced which effect.
Mechanism is described at the gene-regulation level
The proposed action is epigenetic — influencing which genes are expressed rather than binding a receptor. The chromatin-condensation tracking in the human trial found no change, which is a reassuring finding at the nuclear level, but the full mechanistic picture is still being characterised.
Research use only
Material supplied here is strictly for laboratory research and is not for human or veterinary use.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.